Jazz Pharmaceuticals plc (JAZZ) income statement
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$230.26−6.19 (-2.62%)
Close on Nov 20, 2026Market cap $14.95BP/E 75.0Yield –
Jazz Pharmaceuticals plc financial ratios
See a number that looks wrong?